These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32654508)

  • 21. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 22. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.
    Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY
    Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.
    Plagnol V; Woodhouse S; Howarth K; Lensing S; Smith M; Epstein M; Madi M; Smalley S; Leroy C; Hinton J; de Kievit F; Musgrave-Brown E; Herd C; Baker-Neblett K; Brennan W; Dimitrov P; Campbell N; Morris C; Rosenfeld N; Clark J; Gale D; Platt J; Calaway J; Jones G; Forshew T
    PLoS One; 2018; 13(3):e0193802. PubMed ID: 29543828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA.
    Gale D; Lawson ARJ; Howarth K; Madi M; Durham B; Smalley S; Calaway J; Blais S; Jones G; Clark J; Dimitrov P; Pugh M; Woodhouse S; Epstein M; Fernandez-Gonzalez A; Whale AS; Huggett JF; Foy CA; Jones GM; Raveh-Amit H; Schmitt K; Devonshire A; Green E; Forshew T; Plagnol V; Rosenfeld N
    PLoS One; 2018; 13(3):e0194630. PubMed ID: 29547634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methods for Measuring ctDNA in Lymphomas.
    Rossi D; Condoluci A; Spina V; Gaidano G
    Methods Mol Biol; 2019; 1881():253-265. PubMed ID: 30350211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Pipeline for ctDNA Detection Following Primary Tumor Profiling Using a Cancer-Related Gene Sequencing Panel.
    Nishizuka SS; Sato KA; Hachiya T
    Methods Mol Biol; 2019; 1908():229-241. PubMed ID: 30649732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next-generation sequencing in liquid biopsy: cancer screening and early detection.
    Chen M; Zhao H
    Hum Genomics; 2019 Aug; 13(1):34. PubMed ID: 31370908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.
    Serrano C; Vivancos A; López-Pousa A; Matito J; Mancuso FM; Valverde C; Quiroga S; Landolfi S; Castro S; Dopazo C; Sebio A; Virgili AC; Menso MM; Martín-Broto J; Sansó M; García-Valverde A; Rosell J; Fletcher JA; George S; Carles J; Arribas J
    BMC Cancer; 2020 Feb; 20(1):99. PubMed ID: 32024476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
    Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
    Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating Tumor DNA Assays in Clinical Cancer Research.
    Ossandon MR; Agrawal L; Bernhard EJ; Conley BA; Dey SM; Divi RL; Guan P; Lively TG; McKee TC; Sorg BS; Tricoli JV
    J Natl Cancer Inst; 2018 Sep; 110(9):929-934. PubMed ID: 29931312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
    Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
    Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic-Based Multiplex PCR and Next-Generation Sequencing.
    Guan Y; Mayba O; Sandmann T; Lu S; Choi Y; Darbonne WC; Leveque V; Ryner L; Humke E; Tam NWR; Sujathasarma S; Cheung A; Bourgon R; Lackner MR; Wang Y
    J Mol Diagn; 2017 Nov; 19(6):921-932. PubMed ID: 28867605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA.
    Kockan C; Hach F; Sarrafi I; Bell RH; McConeghy B; Beja K; Haegert A; Wyatt AW; Volik SV; Chi KN; Collins CC; Sahinalp SC
    Bioinformatics; 2017 Jan; 33(1):26-34. PubMed ID: 27531099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell-free DNA in blood as a noninvasive insight into the sarcoma genome.
    Namløs HM; Boye K; Meza-Zepeda LA
    Mol Aspects Med; 2020 Apr; 72():100827. PubMed ID: 31703948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
    Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
    Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liquid biopsy enters the clinic - implementation issues and future challenges.
    Ignatiadis M; Sledge GW; Jeffrey SS
    Nat Rev Clin Oncol; 2021 May; 18(5):297-312. PubMed ID: 33473219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA.
    Peng M; Xie Y; Li X; Qian Y; Tu X; Yao X; Cheng F; Xu F; Kong D; He B; Liu C; Cao F; Yang H; Yu F; Xu C; Tian G
    J Med Genet; 2019 Oct; 56(10):647-653. PubMed ID: 30981987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.
    Lee KS; Seo J; Lee CK; Shin S; Choi Z; Min S; Yang JH; Kwon WS; Yun W; Park MR; Choi JR; Chung HC; Lee ST; Rha SY
    Clin Chem; 2022 Dec; 68(12):1519-1528. PubMed ID: 36306340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA.
    Clark TA; Chung JH; Kennedy M; Hughes JD; Chennagiri N; Lieber DS; Fendler B; Young L; Zhao M; Coyne M; Breese V; Young G; Donahue A; Pavlick D; Tsiros A; Brennan T; Zhong S; Mughal T; Bailey M; He J; Roels S; Frampton GM; Spoerke JM; Gendreau S; Lackner M; Schleifman E; Peters E; Ross JS; Ali SM; Miller VA; Gregg JP; Stephens PJ; Welsh A; Otto GA; Lipson D
    J Mol Diagn; 2018 Sep; 20(5):686-702. PubMed ID: 29936259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.